RNTX
Rein Therapeutics Inc.NASDAQHealthcare$1.39+14.88%ClosedMarket Cap: $39.0M
As of 2026-04-07
Valuation
P/E (TTM)
—
PEG
—
P/B
2.09
P/S
0.00
EV/EBITDA
-1.63
DCF Value
$-0.01
FCF Yield
-49.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-281.0%
ROA
-206.4%
ROIC
-120.3%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | NaN% | $-4.0M | $-32.0M | $-1.22 | — |
| FY 2025 | $0.00 | -Infinity% | $-21.9M | $-49.9M | $-1.96 | — |
| Q3 2025 | $0.00 | NaN% | $-5.5M | $-5.6M | $-0.21 | — |
| Q2 2025 | $0.00 | NaN% | $-6.9M | $-6.8M | $-0.28 | — |
| Q1 2025 | $0.00 | NaN% | $-5.6M | $-5.5M | $-2,510.05 | — |
| Q4 2024 | $0.00 | NaN% | $-5.8M | $-41.0M | $-1.89 | — |
| FY 2024 | $0.00 | NaN% | $-65.1M | $-62.9M | $-3.51 | — |
| Q3 2024 | $0.00 | NaN% | $-6.1M | $-5.8M | $-0.27 | — |
| Q2 2024 | $0.00 | NaN% | $-9.0K | $-8.9K | $-0.45 | — |
| Q1 2024 | $0.00 | NaN% | $-7.2K | $-7.1K | $-0.86 | — |
| Q4 2023 | $0.00 | NaN% | $-7.3K | $-7.3K | $-1.54 | — |
| FY 2023 | $0.00 | NaN% | $-16.3K | $-15.7K | $-3.42 | — |